Ownership and insider activity for Allogene Therapeutics, Inc. (ALLO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy.
Price
| Price | $1.69 |
| Market Cap | $583M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-21 | Douglas Earl Martin | S-Sale | 29,697 | $63K |
| 2026-07-01 | Roberts Zachary | A-Award | 476,190 | $1.0M |
| 2026-07-01 | Roberts Zachary | A-Award | 134,530 | |
| 2026-06-18 | Kazam Joshua A | M-Exempt | 47,700 | |
| 2026-06-18 | Kazam Joshua A | A-Award | 95,400 | |
| 2026-06-18 | Kazam Joshua A | M-Exempt | 47,700 | |
| 2026-06-18 | MESSEMER DEBORAH M. | A-Award | 95,400 | |
| 2026-06-18 | Mayo Stephen | A-Award | 144,400 | $289K |
| 2026-06-18 | SATO VICKI L | A-Award | 95,400 | |
| 2026-06-18 | WITTE OWEN N. | A-Award | 95,400 |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 0 | $721.4M | $175.1M | $183.4M | $173.3M | $61.9M | $83.2M | $75.2M | $51.7M |
| Short-term Investments | 0 | 0 | $355.4M | $644.6M | $284.0M | $455.4M | $365.5M | $217.3M | $198.5M |
| Receivables | 0 | $3.1M | $2.4M | 0 | 0 | 0 | $1.7M | $1.9M | $1.5M |
| Inventory | 0 | -$262.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 0 | $468.0M | $544.6M | $845.1M | $471.3M | $528.8M | $459.1M | $303.4M | $257.7M |
| Property, Plant & Equipment | 0 | $41.6M | $100.9M | $160.1M | $181.0M | $196.4M | $163.2M | $131.3M | $112.7M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | $754000 | $151000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 0 | $773.9M | $717.8M | $1.23B | $1.05B | $821.6M | $642.8M | $548.7M | $415.9M |
| Accounts Payable | 0 | $12.3M | $9.2M | $10.4M | $10.3M | $13.9M | $5.9M | $5.4M | $4.3M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $2000 | $29.5M | $33.1M | $94.3M | $47.9M | $53.7M | $37.1M | $35.5M | $32.5M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $2000 | $70.7M | $88.8M | $148.2M | $125.6M | $154.7M | $130.6M | $126.5M | $123.4M |
| Retained Earnings | -$23000 | -$211.5M | -$396.1M | -$646.3M | -$894.6M | -$1.23B | -$1.56B | -$1.82B | -$2.01B |
| Total Equity | -$2000 | $703.2M | $629.0M | $1.08B | $925.2M | $666.9M | $512.2M | $422.2M | $292.5M |
| Total Debt | 0 | $34.5M | $53.0M | $53.8M | $73.1M | $101.1M | $95.1M | $90.8M | $83.3M |
| Net Debt | 0 | -$686.9M | -$477.5M | -$774.1M | -$384.2M | -$416.2M | -$353.6M | -$201.7M | -$167.0M |
| Working Capital | -$2000 | $438.5M | $511.5M | $750.8M | $423.4M | $475.1M | $422.0M | $267.9M | $225.2M |
Financial Health
| Debt / Equity | 0.16 |
| Current Ratio | 10.72 |
Profitability
| Return on Equity | -50.04% |
| Return on Invested Capital | -34.79% |
| Return on Assets | -30.08% |
| Gross Margin | -699.35% |
| Operating Margin | -3886.14% |
| Net Margin | -3566.68% |
Related companies: ACHV · AVIR · CABA · CRBU · EDIT · HUMA · IMMP
Explore sector: Healthcare · Biotechnology
More sections of ALLO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks